

Bisphosphonates2019
Celebrating 50 years
15-17 July 2019 The Edge Sheffield

Outline as at January 2019 - more speakers/faculty to be added

Monday 15 July “The Past”

Introduction and early history

Graham Russell (Sheffield and Oxford, UK)

Individual bisphosphonates: historical perspective

Etidronate

Nelson Watts (Cincinnati, USA)

Alendronate

Steve Cummings (San Francisco, USA)

Risedronate

Mike McClung (Portland, USA)

Zoledronate

Ian Reid (Auckland, New Zealand)

Break and Posters

Clodronate

Eugene McCloskey (Sheffield, UK)

Ibandronate

Dieter Felsenberg (Berlin, Germany)

The Leiden experience

Socrates Papapoulos (Leiden, Netherlands)

Lunch and Posters

Mechanisms of action

How bisphosphonates work, biochemical level

Jukka Mönkkönen (Kuopio, Finland) and **Mike Rogers** (Sydney, Australia)

How bisphosphonates work, tissue level

Speaker tbc

Pharmacological evaluation of bisphosphonates

Serge Cremers (New York, USA)

Action of bisphosphonates on cancer

Philippe Clézardin (Lyon, France)

Imaging

Radiolabelled bisphosphonates for clinical imaging and therapy
Gary Cook (London, UK)

Break and Posters

Pyrophosphate updated

The development of enzyme replacement for hypophosphatasia
Philippe Crine (Montreal, Canada)

Hypophosphatasia: historical perspective and current status
Michael Whyte (St Louis, USA)

Close

Tuesday 16 July "The Present"

Current Issues with the Use of Bisphosphonates

Osteoporosis

Why are bisphosphonates not being used more to prevent fractures (the 'Treatment Gap')
Cyrus Cooper (Southampton and Oxford, UK)

Long-term effects of bisphosphonates on bone
Dennis Black (San Francisco, USA)

Practical guidance for use of bisphosphonates in osteoporosis
Juliet Compston (Cambridge, UK)

Treatment of osteoporosis with anabolic and antiresorptive drugs: combined and sequential approaches
Bente Langdahl (Aarhus, Denmark)

The challenge of long-term adherence, the role of bone turnover markers
Richard Eastell (Sheffield, UK)

Break and Posters

Bone and Cancer

Disease modifying effects of bisphosphonates in cancer
Rob Coleman (Sheffield, UK)

The use of bisphosphonates across solid tumours with established bone metastases
Janet Brown (Sheffield, UK)

Myeloma bone disease and bisphosphonates
Matthew Drake (Rochester, USA)

Snap posters

Lunch and Posters

Rare Bone Disease

Osteogenesis imperfecta
Nick Bishop (Sheffield, UK)

Fibrous dysplasia
Roland Chapurlat (Lyon, France)

Orthopaedic Diseases

Use of bisphosphonates in orthopaedic applications
Mark Wilkinson (Sheffield, UK)

Break and Posters

Paget's Disease

Management of Paget's Disease
Stuart Ralston (Edinburgh, UK)

Litigation Matters

Liability litigation: AFF, ONJ
Ron Dhindsa (Washington DC, USA)

Is the patent system fit for purpose?
Sir Robin Jacob

Close

Wednesday 17 July “The Future”

Ageing and Lifespan

Effect of bisphosphonates on lifespan
Jacqueline Center (Sydney, Australia)

Musculoskeletal effects

Osteoarthritis and bone marrow lesions
Erik Fink Eriksen (Oslo, Norway)

Bisphosphonates and pain
Thomas Tzschentke (Aachen, Germany)

Burn injury and restoration of muscle function
Gordon Klein (Galveston, USA)

Bone and muscle interactions in cancer
Theresa Guise (Indianapolis, USA)

Lunch and Posters

Mineralisation

Biological mineralisation mechanisms
Marc McKee (Montreal, Canada)

General arterial calcification of infancy, etidronate and ENPP1 replacement
Demetrios Braddock (New Haven, USA)

New Bisphosphonates, mechanisms, and applications

Non classical actions - osteocytes, connexins, IG9402
Lilian Plotkin and **Teresita Bellido** (Indianapolis, USA)

New bisphosphonates and use for drug delivery
Hal Ebetino (Rochester, USA)

Dental applications
Parish Sedghizadeh (Los Angeles, USA)

Delivery of chloroquine and anti-cancer agents to bone
Brendan Boyce (Rochester, USA)

Discussion and Close